巴曲酶联合依达拉奉治疗急性脑梗死的疗效观察

目的：探讨巴曲酶联合依达拉奉治疗急性脑梗死的临床疗效，并评估其安全性。方法选取2010年1月～2013年12月普宁市人民医院收治的急性脑梗死患者60例，采取随机双盲的方法将患者均分2组（n=30）。常规治疗组给予脱水剂、脑细胞保护类药物，全程监控血压、血糖，纠正水电解质紊乱并维持酸碱平衡状态等急性脑梗死常规治疗方法；联合治疗组在常规治疗的基础上给予巴曲酶联合依达拉奉静脉滴注治疗。比较2组患者治疗前后神经功能缺损情况、日常生活能力改善情况及治疗有效率。结果联合治疗组患者神经功能缺损评分及日常生活能力评分与常规治疗组比较，差异有统计学意义（P＜0.05）；联合治疗组患者治疗总有效率明显高于常规治疗组，差异有统计学意义（P＜0.05）。结论巴曲酶联合依达拉奉治疗急性脑梗死取得了较好的临床效果，能够显著改善患者神经功能缺损症状，提高日常生活能力，并无明显不良反应出现，值得临床推广应用。

Objective To investigate batroxobin edaravone treatment of acute cerebral infarction clinical efficacy and safety evaluation of its use, it is desirable to provide a basis for clinical use. Methods 60 patients with acute cerebral infarction in our hospital, randomized, double-blind approach would take the average score of patients treated with conventional combination therapy group （n=30）. Conventional treatment group was given a dehydrating agent to protect brain cells drugs, full control of blood pressure, blood sugar, and maintain correct water and electrolyte imbalance, such as acid-base balance of conventional treatment of acute cerebral infarction . Combination therapy group were given batroxobin edaravone infusion therapy based on conventional therapy. Neurological deficit situations, the ability to improve the daily lives of patients were compared before and after treatment and the treatment efficiency. Results The patients treated with neurological deficit scores and ADL score compared with the conventional treatment group were significantly different, the difference was statistically significant （P〈0.05）;Treatment of patients with combined treatment group was significantly higher than conventional therapy group （P〈0.05）. Conclusion Batroxobin edaravone treatment of acute cerebral infarction achieved good clinical results, can significantly improve symptoms in patients with neurological deficit , improving activities of daily living, there is no significant adverse reactions , worthy of clinical application.